Document Detail


Determinants of summiting success and acute mountain sickness on Mt Kilimanjaro (5895 m).
MedLine Citation:
PMID:  20030437     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To determine the incidence of acute mountain sickness (AMS), the frequency of summiting success, and the factors that affect these in trekkers on Kilimanjaro, one of the world's most summitted high-altitude peaks. METHODS: The study group comprised 312 trekkers attempting Mt Kilimanjaro summit by the Marango Route. Trekkers ascended over 4 or 5 days along a fixed ascent profile, stopping at 3 huts on ascent (2700 m, 3700 m, and 4700 m) before attempting the summit. Researchers were stationed at each hut for 16 days. Each night we measured heart rate, respiratory rate, blood pressure, oxygen saturation, and Lake Louise Score. We recorded the highest altitude that trekkers reached on the mountain. RESULTS: Of 181 complete sets of data, 111 (61%) trekkers reached the summit, and 139 (77%) developed AMS. Physiological results were not related to summit success. The incidence of AMS and summiting success were similar in those on the 4- or 5-day route. Trekkers on the 5-day route who used acetazolamide were less likely to develop AMS and more likely to summit than were those not taking acetazolamide (P = <.05); this difference was not present with trekkers on the 4-day route. CONCLUSIONS: The risk of developing AMS is high on Mt Kilimanjaro. Although taking an extra day to acclimatize with the use of acetazolamide did provide some protection against AMS, ideally trekkers need a more gradual route profile for climbing this mountain.
Authors:
Andrew J Davies; Nicholas S Kalson; Suzy Stokes; Mark D Earl; Adam G Whitehead; Hannah Frost; Ian Tyrell-Marsh; Jon Naylor
Related Documents :
8725477 - Effect of low altitude on glycolytic key enzymes in red blood cells.
11748047 - Targeted disruption of the gene for natriuretic peptide receptor-a worsens hypoxia-indu...
23375187 - Changes in cardiovascular risk associated with phentermine and topiramate extended-rele...
3521277 - The effect of naproxen on acute mountain sickness and vascular responses to hypoxia.
11981707 - Operative procedure and volumetry in experimental biomechanical hearts.
7315437 - Blood pressure in the fetal guinea-pig.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Wilderness & environmental medicine     Volume:  20     ISSN:  1545-1534     ISO Abbreviation:  Wilderness Environ Med     Publication Date:  2009  
Date Detail:
Created Date:  2009-12-24     Completed Date:  2010-03-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9505185     Medline TA:  Wilderness Environ Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  311-7     Citation Subset:  IM    
Affiliation:
Manchester Altitude Research Society, University of Manchester Medical School, Manchester, UK. andrewjohndavies@doctors.org.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acclimatization / physiology*
Acetazolamide / therapeutic use
Acute Disease
Altitude Sickness / epidemiology,  prevention & control*
Carbonic Anhydrase Inhibitors / therapeutic use
Humans
Kenya / epidemiology
Risk Factors
Time Factors
Chemical
Reg. No./Substance:
0/Carbonic Anhydrase Inhibitors; 59-66-5/Acetazolamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Subjective sleep quality alterations at high altitude.
Next Document:  Injury and illness encountered in shenandoah national park.